Company Filing History:
Years Active: 2009-2019
Title: Jiayi Wu: Innovator in Cancer Treatment
Introduction
Jiayi Wu is a prominent inventor based in Brookline, MA (US), known for her significant contributions to cancer treatment. With a total of 4 patents, she has focused her research on innovative therapies that combine existing cancer treatments to enhance their effectiveness.
Latest Patents
One of her latest patents involves the use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer. This invention features methods for treating cancer in patients by administering eribulin alongside one or more PARP inhibitors, and optionally, a platinum-based antineoplastic drug. The invention is based on the observation that combinations of eribulin mesylate and a PARP inhibitor, such as E7449, show improved antitumor effects. Another notable patent by Jiayi Wu is the use of eribulin and lenvatinib as combination therapy for treating diseases associated with excessive cellular proliferation, including cancer.
Career Highlights
Throughout her career, Jiayi Wu has worked with notable companies in the pharmaceutical industry, including Eisai R&D Management Co., Ltd. and Eisai Inc. Her work has significantly impacted the development of cancer therapies, showcasing her dedication to improving patient outcomes.
Collaborations
Jiayi Wu has collaborated with esteemed colleagues such as Sergei I Agoulnik and Yimin Jiang, further enhancing her research and contributions to the field of cancer treatment.
Conclusion
Jiayi Wu's innovative work in cancer therapy exemplifies her commitment to advancing medical science. Her patents reflect a deep understanding of the complexities of cancer treatment and a desire to improve therapeutic options for patients.